Grant received in 2024.
DCCC has funded 200,000 DKK to the project.
Approximately 65% of Danish breast cancer patients are overweight, and 21% suffer from obesity. Overweight is known to increase the risk of breast cancer recurrence, which is a concerning factor.
In recent years, several medications for obesity have been introduced to the market, which are used by many, including cancer patients. Unfortunately, there is a lack of evidence regarding the safety of concurrently using weight loss medication alongside cancer treatment. There is also uncertainty about whether cancer patients will experience the same weight-reducing effect of the medication as individuals without cancer or cancer treatment.
This initiative aims to prepare a national clinical trial to investigate the effect and safety of medically induced weight loss during cancer treatment. The purpose of this study is to determine whether it is effective and safe for breast cancer patients to use weight loss medication during their cancer treatment. The results are expected to significantly contribute to clinical practice and guidance regarding medically induced weight loss in cancer patients.
Multidisciplinary organisation
This initiative is anchored in the National Network for Obesity and Cancer Research (ObeCaRe).
Project stakeholders
- Deirdre Cronin Fonton, Professor, PhD, Department of Clinical Medicine, Aarhus University, Aarhus University Hospital
- Signe Borgquist, Chair Professor, MD, PhD, Department of Oncology, Aarhus University Hospital. Primary contact, e-mail: signe.borgquist@oncology.au.dk
- Jan Frystyk, MD, PhD, Head of Department, Medical Endocrinology, Odense University Hospital, professor, Research unit of Endocrinology, University of Southern Denmark
- Robert Zachariae, Professor, Department of Psychology and Behavioural Sciences, Aarhus University, Dr.Med.,Department of Oncology, Aarhus University Hospital
- Jens Meldgaard Bruun, Clinical Professor, MD, PhD., Steno Diabetes Center Aarhus, Aarhus University Hospital